SAN DIEGO, March 16, 2018 /PRNewswire/ -- OncoSec Medical
Incorporated (OncoSec) (NASDAQ: ONCS), a company developing
intratumoral cancer immunotherapies, today announced that
Daniel J. O'Connor, Chief Executive
Officer of OncoSec, will present at the Oppenheimer 28th Annual
Healthcare Conference being held March
20-21, 2018 at the Westin New York Grand Central in
New York City.
Mr. O'Connor will present OncoSec's corporate growth strategy
and its focus on developing DNA-based intratumoral immunotherapies
that utilize the company's proprietary ImmunoPulse®
technology, which is designed to enhance the local delivery and
uptake of DNA-based immune-targeting agents. In Phase 1 and 2
clinical trials, ImmunoPulse® IL-12 has demonstrated a
favorable safety profile, evidence of anti-tumor activity in the
treatment of various solid tumors, and the potential to reach
beyond the site of local treatment to initiate a systemic immune
response.
Details of OncoSec's presentation are as follows:
Event:
|
|
Oppenheimer &
Co. 28th Annual Healthcare Conference
|
Date:
|
|
March 20,
2018
|
Time:
|
|
1:20 PM
(ET)
|
Location:
|
|
The Westin New York
Grand Central, New York, NY
|
In addition to the presentation, management will be available to
participate in one-on-one meetings with qualified members of the
investor community who are registered to attend the conference.
To view the live webcast, please access the following link at
the time of the presentation:
https://www.veracast.com/webcasts/opco/healthcare2018/72115452478.cfm.
An archived version of the webcast will be available for 90 days on
OncoSec's website: http://www.oncosec.com.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
Janine McCargo / David Schemelia
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
jmccargo@tiberend.com
dschemelia@tiberend.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-the-oppenheimers-28th-annual-healthcare-conference-300615144.html
SOURCE OncoSec Medical Incorporated